Michael Saunders
Vice president
biomedical science
ArgenX
Netherlands
Biography
Michael Saunders has been discovering novel drugs and selecting therapeutic targets for 25 years. At argenx for more than 6 years, he is currently responsible for External Research and the Innovative Access Program. At argenx, he has contributed to the discovery of four antibodies in clinical and preclinical development, for establishment and maintenance of academic collaborations and Alliance Management with Pharma partners (Shire, Bayer, Eli Lilly) and obtaining 4 Research Grants (>9M€).
Research Interest
Biomedical Systems & Emerging Technologies
